Journal article

The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial

Susan R Davis, Penelope J Robinson, Fiona Jane, Shane White, Kristy A Brown, Sofie Piessens, Andrew Edwards, Jane McNeilage, Jillian Woinarski, Mitchell Chipman, Robin J Bell

CLINICAL ENDOCRINOLOGY | WILEY | Published : 2018

Abstract

BACKGROUND: We investigated whether metformin prevents tamoxifen-induced endometrial changes and insulin resistance (IR) after a diagnosis of breast cancer. METHODS: This was a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. Postmenopausal women with hormone receptor-positive breast cancer taking tamoxifen were randomly allocated to metformin 850 mg or identical placebo, twice daily, for 52 weeks. Outcome measures included double endometrial thickness (ET) measured by transvaginal ultrasound, fasting insulin, glucose and IR estimated by the homeostasis model of assessment (HOMA-IR). RESULTS: A total of 112 women were screened and 102 randomized. Results are..

View full abstract

University of Melbourne Researchers